​

Connect Biopharma (CNTB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CNTB Stock Forecast

Connect Biopharma (CNTB) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $9.00 and a low of $9.00. This represents a 268.85% increase from the last price of $2.44.

$1 $2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $9 Low: $9 Last Closed Price: $2.44

CNTB Stock Rating

Connect Biopharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

CNTB Price Target Upside V Benchmarks

TypeNameUpside
StockConnect Biopharma268.85%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$9.00$9.00$9.00
Last Closing Price$2.44$2.44$2.44
Upside/Downside268.85%268.85%268.85%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-4---4
Nov, 2513---4
Oct, 2512---3
Sep, 2512---3
Aug, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 01, 2025Thomas FlatenLake Street$9.00$2.86214.69%268.85%
May 05, 2022Joseph CatanzaroPiper Sandler$1.50$0.8282.93%-38.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 01, 2025Lake StreetBuyinitialise
Oct 31, 2025BTIGBuyinitialise
Jun 12, 2025H.C. WainwrightBuyBuyinitialise
Sep 06, 2024H.C. WainwrightBuyBuyhold
Apr 17, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2022Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.08$-0.28----
Avg Forecast$-5.47$-1.42$-5.30$-2.72$-0.07$-1.36
High Forecast$-5.47$-1.42$-5.30$-2.72$-0.07$-1.36
Low Forecast$-5.47$-1.42$-5.30$-2.72$-0.07$-1.36
Surprise %-80.26%-80.28%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$26.03M----
Avg Forecast$149.90M$170.76M$282.56M$221.75M$444.94M$370.54M
High Forecast$149.90M$170.76M$282.56M$221.75M$445.80M$370.54M
Low Forecast$149.90M$170.76M$282.56M$221.75M$444.07M$370.54M
Surprise %--84.75%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-59.50M$-15.63M----
Avg Forecast$-301.07M$-78.04M$-291.79M$-149.69M$-4.10M$-74.84M
High Forecast$-301.07M$-78.04M$-291.79M$-149.69M$-4.10M$-74.84M
Low Forecast$-301.07M$-78.04M$-291.79M$-149.69M$-4.10M$-74.84M
Surprise %-80.24%-79.97%----

CNTB Forecast FAQ

Is Connect Biopharma stock a buy?

Connect Biopharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Connect Biopharma is a favorable investment for most analysts.

What is Connect Biopharma's price target?

Connect Biopharma's price target, set by 5 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $9 at the low end to $9 at the high end, suggesting a potential 268.85% change from the previous closing price of $2.44.

How does Connect Biopharma stock forecast compare to its benchmarks?

Connect Biopharma's stock forecast shows a 268.85% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Connect Biopharma over the past three months?

  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Connect Biopharma’s EPS forecast?

Connect Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.3, marking a 1792.86% increase from the reported $-0.28 in 2024. Estimates for the following years are $-2.72 in 2026, $-0.07 in 2027, and $-1.36 in 2028.

What is Connect Biopharma’s revenue forecast?

Connect Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $282.56M, reflecting a 985.37% increase from the reported $26.03M in 2024. The forecast for 2026 is $221.75M, followed by $444.94M for 2027, and $370.54M for 2028.

What is Connect Biopharma’s net income forecast?

Connect Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-292M, representing an 1767.13% increase from the reported $-15.628M in 2024. Projections indicate $-150M in 2026, $-4.099M in 2027, and $-74.843M in 2028.